Skip to main content

Table 2 Characteristics of the study

From: Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty

Study Design Country No. of patients Age (years) Sex (male/female) BMI (kg/m2) Follow-up Conclusion
IV IA IV IA IV IA IV IA
Jules-Elysee et al. [14] RCT USA 31 32 65.6 ± 8.4 65.0 ± 6.9 11/20 12/20 31.6 ± 7.1 31.1 ± 5.2 Unclear IV > IA
Laoruengthana et al. [13] RCT Thailand 76 75 64.01 ± 7.68 64.81 ± 8.06 62/14 63/12 27.8 ± 5.2 27.6 ± 4.2 Unclear IA > IV
Zhang et al. [15, 52] RCT China 50 50 63.12 ± 8.79 59.86 ± 12.01 12/38 10/40 23.9 ± 4.7 25.0 ± 4.3 6 months IA > IV
Abdel et al. [20] RCT USA 320 320 66 67 127/193 133/187 31.3 31.6 Unclear IV > IA
Ahmed et al. [23] RCT Pakistan 70 70 63.30 ± 9.51 64.39 ± 9.07 28/42 32/38 Unclear Unclear Unclear IA > IV
López-Hualda et al. [21] RCT Spain 30 30 73.1 ± 7.3 72.9 ± 7.1 6/24 11/19 Unclear Unclear 1 year IA > IV
George et al. [16] RCT India 55 58 64.1 63.8 24/31 14/44 29.4 31.1 6 weeks Neutral
Subramanyam et al. [19] RCT India 91 91 62.9 ± 6.8 62.7 ± 7.5 31/60 35/56 28.9 29.9 6 weeks Neutral
Wei et al. [18] RCT China 32 32 66.47 ± 8.28 66.43 ± 7.69 14/18 16/16 32.4 ± 3.7 34.2 ± 5.0 3 months Neutral
Goyal et al. [36] RCT Australia 85 83 68.8 ± 7.4 66.7 ± 8.9 40/47 38/43 30.3 ± 6.1 31.0 ± 5.3 1 month Neutral
Lacko et al. [22] RCT Slovakia 30 30 68.4 ± 7.2 67.5 ± 7.7 12/18 13/17 31.1 ± 4.7 31.9 ± 4.7 3 months IV > IA
Maniar et al. [33] RCT India 50 25 65.7 ± 7.6 62.2 ± 7.1 7/43 2/23 30.2 ± 4.5 30.3 ± 3.9 3 months Neutral
Prakash et al. [26] RCT India 50 50 70.2 71 NR NR Unclear Unclear 3 months IV > IA
Song et al. [35] RCT South Korea 50 50 69.2 ± 6.4 69.8 ± 6.8 6/44 8/42 26.52 ± 3.3 26.96 ± 4.2 3 months Neutral
Stowers et al. [24] RCT New Zealand 51 60 71 ± 8.6 70 ± 8.5 27/24 28/32 31.2 ± 5.5 31.2 ± 5.5 6 months Neutral
Uğurlu et al. [34] RCT USA 40 42 69.4 ± 7.5 70.6 ± 8.6 11/29 9/33 30.8 ± 5.3 31.1 ± 5.4 10 days Neutral
Wang et al. [11, 23] RCT China 50 50 67.42 ± 8.20 67.98 ± 5.97 14/36 14/36 26.7 ± 3.4 25.9 ± 3.8 5 weeks IA > IV
Zekcer et al. [25] RCT Brazil 30 30 65.7 65.7 6/24 9/21 Unclear Unclear Unclear Neutral
Aggarwal et al. [39] RCT India 35 35 58.77 ± 10.14 55.66 ± 8.71 13/22 12/23 26.33 ± 3.79 27.33 ± 4.63 6 months IA > IV
Chen et al. [29, 53] RCT Singapore 50 50 65 ± 8 65 ± 8 15/35 10/40 28 ± 5 28 ± 7 1 month Neutral
Drosos et al. [38] RCT Greece 30 30 69.27 ± 7.21 71.10 ± 6.32 6/24 6/24 32.79 ± 5.04 33.38 ± 6.08 1 month Neutral
Keyhani et al. [42] RCT Iran 40 40 68.4 ± 10.4 67 ± 11.9 26/14 23/17 32.7 ± 5.5 31.3 ± 5.4 2 weeks Neutral
May et al. [37] RCT USA 69 62 65.0 ± 9.6 63.0 ± 10.6 11/58 18/44 33.8 33.8 1 month Neutral
Pinsornsak et al. [41] RCT Thailand 30 30 69.97 ± 7.55 67.63 ± 7.96 7/23 5/25 26.52 ± 3.7 27.96 ± 4.99 2 weeks Neutral
Tzatzairis et al. [40] RCT Greece 40 40 69.55 ± 6.61 69.10 ± 8.68 9/31 7/33 32.60 ± 4.09 32.60 ± 4.50 6 weeks Neutral
Aguilera et al. [43] RCT Spain 50 50 72.49 ± 7.68 72.53 ± 6.60 38/12 32/18 30.20 ± 4.10 30.89 ± 4.37 2 months Neutral
Digas et al. [44] RCT Greece 30 30 70 ± 6.5 71 ± 7.0 2/28 7/23 Unclear Unclear 1 year IA > IV
Öztaş et al. [45] RCT Turkey 30 30 68.56 67.06 5/25 4/26 Unclear Unclear 3 months IA > IV
Gomez-Barrena et al. [46] RCT Spain 39 39 71.8 ± 10.3 70.1 ± 9.1 25/14 26/13 30.2 ± 4.2 30.4 ± 4.1 1 month Neutral
Patel et al. [47] RCT USA 42 47 64.9 ± 7.8 64.8 ± 9.7 10/32 13/34 35.8 ± 8.6 32.7 ± 7.0 2 weeks Neutral
Sarzaeem et al. [48] RCT Iran 50 100 66.9 ± 7.2 67.8 ± 7.2 7/43 13/87 31.6 ± 2.7 31.5 ± 3.4 Unclear Neutral
Soni et al. [49] RCT India 40 40 69.05 ± 4.10 69.45 ± 4.71 19/21 17/23 Unclear Unclear 6 weeks Neutral
Seo et al. [50] RCT South Korea 50 50 66.8 ± 6.3 67.5 ± 6.6 6/44 5/45 28.1 ± 3.1 27.8 ± 3.5 2 months IA > IV
Maniar et al. [51] RCT India 160 40 67.4 ± 8.1 67.4 ± 7.9 36/124 6/34 29.2 ± 5.4 30.9 ± 5.2 3 months Neutral
  1. RCT randomized controlled trial, IV intravenous group, IA intra-articular group, TKA total knee arthroplasty, BMI body mass index